| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,966 | 4,543 | 3,604 | 3,826 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 953 | 1,730 | 699 | 756 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 23 % | 17 % | 18 % | 19 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 |
Biocon
331.30
+2.15
(0.65%)
Market Cap
39,775.88 Cr
EPS
8.55
PE Ratio
51.09
Dividend Yield
0.15 %
Industry
Healthcare52 Week High
404.70
52 Week Low
259.85
PB Ratio
1.88
Debt to Equity
0.91
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from15 analysts
Company News
View All News
Biocon's Subsidiary Secures U.S. Market Entry for Eylea Biosimilar5 days ago
Biocon's subsidiary has obtained approval for market entry of Yesafili™, an interchangeable biosimilar to Eylea, in the United States. This development represents a significant milestone for the company in expanding its presence in the U.S. pharmaceutical market, particularly in the ophthalmology sector.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,751.50 | #1 4,20,243.52 | 34.43 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 56.15 | |
5,640.00 | 1,49,724.28 | 73.95 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 49.32 | |
1,515.20 | 1,22,369.82 | 24.22 | 26,520.70 | 14.17 | 4,155 | 47.38 | 58.14 | |
3,254.80 | 1,10,157.22 | 58.55 | 10,785.70 | 11.59 | 1,656 | 13.54 | 57.00 | |
2,581.60 | 1,06,511.27 | 50.98 | 10,615.60 | 19.57 | 1,942 | -16.38 | 65.51 | |
1,163.60 | 97,097.23 | #1 18.01 | 28,905.40 | 12.36 | 5,578 | 1.69 | 53.92 | |
1,937.20 | 88,441.11 | 30.81 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 44.61 | |
831.55 | 83,673.39 | 18.24 | 19,831.50 | 13.82 | 3,831 | 29.92 | 39.09 | |
1,171.60 | 68,046.72 | 18.66 | 29,559.20 | 17.55 | 3,169 | -10.04 | 56.33 | |
30,690.00 | 65,214.11 | 48.91 | 6,097.20 | 10.80 | 1,201 | 16.01 | 56.24 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
35.25 %
Net Income Growth
101.84 %
Cash Flow Change
59.45 %
ROE
79.37 %
ROCE
103.31 %
EBITDA Margin (Avg.)
6.64 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,889 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,039 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,447 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Board Meeting Intimation for To Consider And Approve The Proposal For Raising Of Funds.
1 hour ago
1 hour agoAnnouncement under Regulation 30 (LODR)-Credit Rating4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20185 days ago
5 days agoNotification To Stock Exchanges9 days ago
9 days agoCertificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Pod1/P/CIR/2024/54
Dated May 22 2024.9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoBoard Meeting Outcome for Outcome Of Board Meeting - Disclosure Under Reg 30Apr 04, 2025
Apr 04, 2025Board Meeting Outcome for Outcome Of Board Meeting - Disclosure Under Reg 30Apr 04, 2025
Apr 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 02, 2025
Apr 02, 2025Board Meeting Intimation for Board Meeting IntimationApr 02, 2025
Apr 02, 2025Board Meeting Intimation for Board Meeting IntimationApr 02, 2025
Apr 02, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 02, 2025
Apr 02, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 02, 2025
Apr 02, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 02, 2025
Apr 02, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-CessationApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-CessationApr 01, 2025
Apr 01, 2025Board Meeting Intimation for Intimation For The Board Meeting Pursuant To Regulation 29(1)(D) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Raising Of FundsApr 01, 2025
Apr 01, 2025Board Meeting Intimation for Intimation For The Board Meeting Pursuant To Regulation 29(1)(D) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Raising Of FundsApr 01, 2025
Apr 01, 2025Announcement Under Regulation 30Mar 29, 2025
Mar 29, 2025Reminder Letter To Shareholders For Claiming Unclaimed Dividend And Updation Of KYC InformationMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 28, 2025
Mar 28, 2025Notification To Stock ExchangeMar 24, 2025
Mar 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 07, 2025
Mar 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 06, 2025
Mar 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Mar 06, 2025Notification To Stock ExchangesMar 04, 2025
Mar 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2025
Mar 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Feb 28, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2025
Feb 27, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2025
Feb 27, 2025Announcement Under Regulation 30Feb 25, 2025
Feb 25, 2025Announcement Under Regulation 30Feb 25, 2025
Feb 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2025
Feb 24, 2025Notification To Stock ExchangeFeb 18, 2025
Feb 18, 2025Record Date Intimation For Commercial PapersFeb 17, 2025
Feb 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2025
Feb 06, 2025Corporate PresentationFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2025
Feb 01, 2025Technical Indicators
RSI(14)
Neutral 49.32
ATR(14)
Less Volatile 12.45
STOCH(9,6)
Neutral 40.08
STOCH RSI(14)
Neutral 67.52
MACD(12,26)
Bearish -0.24
ADX(14)
Weak Trend 12.57
UO(9)
Bearish 46.87
ROC(12)
Downtrend And Accelerating -4.12
WillR(14)
Neutral -44.69
About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
13 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
